Cardiac Pathophysiology and the Future of Cardiac Therapies in Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is a devastating disease featuring skeletal muscle wasting, respiratory insufficiency, and cardiomyopathy. Historically, respiratory failure has been the leading cause of mortality in DMD, but recent improvements in symptomatic respiratory management have extended the life expectancy of DMD patients. With increased longevity, the clinical relevance of heart disease in DMD is growing, as virtually all DMD patients over 18 year of age display signs of cardiomyopathy. This review will focus on the pathophysiological basis of DMD in the heart and discuss the therapeutic approaches currently in use and those in development to treat dystrophic cardiomyopathy. The first section will describe the aspects of the DMD that result in the loss of cardiac tissue and accumulation of fibrosis. The second section will discuss cardiac small molecule therapies currently used to treat heart disease in DMD, with a focus on the evidence supporting the use of each drug in dystrophic patients. The final section will outline the strengths and limitations of approaches directed at correcting the genetic defect through dystrophin gene replacement, modification, or repair. There are several new and promising therapeutic approaches that may protect the dystrophic heart, but their limitations suggest that future management of dystrophic cardiomyopathy may benefit from combining gene-targeted therapies with small molecule therapies. Understanding the mechanistic basis of dystrophic heart disease and the effects of current and emerging therapies will be critical for their success in the treatment of patients with DMD.

• Publication year

  2019

• Venue

  International Journal of Molecular Sciences

• Publication date

  2019-08-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.3390/ijms20174098PMID 31443395PMCID 6747383
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Life-Long AAV-Mediated CRISPR Genome Editing in Dystrophic Heart Improves Cardiomyopathy without Causing Serious Lesions in mdx Mice.

  2019cited by this paper
• Acute myocardial injury in mdx hearts ameliorated by ARB but not ACE inhibitor treatment

  2019cited by this paper
• Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy

  2019cited by this paper
• Antisense oligonucleotides for the treatment of cardiomyopathy in Duchenne muscular dystrophy.

  2019cited by this paper
• Cardiomyocytes facing fibrotic conditions re-express extracellular matrix transcripts.

  2019cited by this paper
• CRISPR Correction of Duchenne Muscular Dystrophy.

  2019cited by this paper
• Simvastatin provides long‐term improvement of left ventricular function and prevents cardiac fibrosis in muscular dystrophy

  2019cited by this paper
• Acute AT1R blockade prevents isoproterenol-induced injury in mdx hearts.

  2019cited by this paper
• The Role of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Duchenne Muscular Dystrophy Cardiomyopathy.

  2019cited by this paper
• Defective Flux of Thrombospondin-4 through the Secretory Pathway Impairs Cardiomyocyte Membrane Stability and Causes Cardiomyopathy

  2018cited by this paper
• Dietary supplementation with ketoacids protects against CKD-induced oxidative damage and mitochondrial dysfunction in skeletal muscle of 5/6 nephrectomised rats

  2018cited by this paper
• Exon-skipping advances for Duchenne muscular dystrophy.

  2018cited by this paper
• Applications of CRISPR/Cas9 for the Treatment of Duchenne Muscular Dystrophy

  2018cited by this paper
• Off-Label Use of Ataluren in Four Non-ambulatory Patients With Duchenne Muscular Dystrophy: Effects on Cardiac and Pulmonary Function and Muscle Strength

  2018cited by this paper
• Muscle membrane integrity in Duchenne muscular dystrophy: recent advances in copolymer-based muscle membrane stabilizers

  2018cited by this paper
• Long-term Evaluation of AAV-CRISPR Genome Editing for Duchenne Muscular Dystrophy

  2018cited by this paper
• Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management.

  2018influential reference
• Low- and High-renin Heart Failure Phenotypes with Clinical Implications.

  2018cited by this paper
• Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy

  2018cited by this paper
• AAV CRISPR editing rescues cardiac and muscle function for 18 months in dystrophic mice.

  2018cited by this paper
• NADPH oxidase mediates microtubule alterations and diaphragm dysfunction in dystrophic mice

  2018cited by this paper
• Loss of peroxiredoxin-2 exacerbates eccentric contraction-induced force loss in dystrophin-deficient muscle

  2018cited by this paper
• Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan.

  2018cited by this paper
• Advances in the diagnosis and management of cardiomyopathy in Duchenne muscular dystrophy.

  2018cited by this paper
• Deficit in PINK1/PARKIN-mediated mitochondrial autophagy at late stages of dystrophic cardiomyopathy

  2018cited by this paper
• Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy

  2018cited by this paper
• Regulation of fibrosis in muscular dystrophy.

  2018cited by this paper
• ACE inhibition to slow progression of myocardial fibrosis in muscular dystrophies.

  2017cited by this paper
• Corrigendum: Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy

  2017cited by this paper
• Predictors of Death in Adults With Duchenne Muscular Dystrophy–Associated Cardiomyopathy

  2017cited by this paper
• MG53 is dispensable for T-tubule maturation but critical for maintaining T-tubule integrity following cardiac stress.

  2017cited by this paper
• Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy

  2017cited by this paper
• Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy

  2017cited by this paper
• Reducing sarcolipin expression mitigates Duchenne muscular dystrophy and associated cardiomyopathy in mice

  2017cited by this paper
• Progression of Duchenne Cardiomyopathy Presenting with Chest Pain and Troponin Elevation

  2017cited by this paper
• Mutation-Based Therapy for Duchenne Muscular Dystrophy: Antisense Treatment Arrives in the Clinic.

  2017cited by this paper
• All-Atom Molecular Dynamics-Based Analysis of Membrane-Stabilizing Copolymer Interactions with Lipid Bilayers Probed under Constant Surface Tensions.

  2017cited by this paper
• Progress toward Gene Therapy for Duchenne Muscular Dystrophy.

  2017cited by this paper
• Cardiac macrophage biology in the steady-state heart, the aging heart, and following myocardial infarction

  2017cited by this paper
• AT1 receptor signaling pathways in the cardiovascular system

  2017cited by this paper
• A Five-Repeat Micro-Dystrophin Gene Ameliorated Dystrophic Phenotype in the Severe DBA/2J-mdx Model of Duchenne Muscular Dystrophy

  2017cited by this paper
• Transient receptor potential channel 6 regulates abnormal cardiac S-nitrosylation in Duchenne muscular dystrophy

  2017cited by this paper
• Roles of Angiotensin Peptides and Recombinant Human ACE2 in Heart Failure.

  2017cited by this paper
• Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy

  2017cited by this paper
• Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: results of a two-year open-label extension trial

  2017cited by this paper
• Dystrophic Cardiomyopathy—Potential Role of Calcium in Pathogenesis, Treatment and Novel Therapies

  2017cited by this paper
• Current Translational Research and Murine Models For Duchenne Muscular Dystrophy

  2016cited by this paper
• Clinical potential of ataluren in the treatment of Duchenne muscular dystrophy

  2016cited by this paper
• Angiotensin II type 2 receptor (AT2R) in renal and cardiovascular disease.

  2016cited by this paper
• Absence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca2+, Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy.

  2016influential reference
• Duchenne Muscular Dystrophy Mice and Men: Can Understanding a Genetic Cardiomyopathy Inform Treatment of Other Myocardial Diseases?

  2016cited by this paper
• Activation of Both the Calpain and Ubiquitin-Proteasome Systems Contributes to Septic Cardiomyopathy through Dystrophin Loss/Disruption and mTOR Inhibition

  2016cited by this paper
• Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy

  2016cited by this paper
• Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized Trials.

  2016cited by this paper
• Dystrophin-Deficient Cardiomyopathy.

  2016influential reference
• Hypoxia-induced cardiac injury in dystrophic mice.

  2016cited by this paper
• Myeloid cells are capable of synthesizing aldosterone to exacerbate damage in muscular dystrophy.

  2016cited by this paper
• In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy

  2016cited by this paper
• The Clinical Outcome Study for dysferlinopathy

  2016cited by this paper
• Independent variability of microtubule perturbations associated with dystrophinopathy.

  2016cited by this paper
• Thrombospondin expression in myofibers stabilizes muscle membranes

  2016cited by this paper
• X-Linked Dilated Cardiomyopathy: A Cardiospecific Phenotype of Dystrophinopathy

  2015cited by this paper
• Structure-Function Basis of Attenuated Inverse Agonism of Angiotensin II Type 1 Receptor Blockers for Active-State Angiotensin II Type 1 Receptor

  2015cited by this paper
• Chronic effects of losartan on the muscles and the serologic profiles of mdx mice.

  2015cited by this paper
• The Pathogenesis and Therapy of Muscular Dystrophies.

  2015cited by this paper
• Role of sodium and calcium dysregulation in tachyarrhythmias in sudden cardiac death.

  2015cited by this paper
• Cognitive and Neurobehavioral Profile in Boys With Duchenne Muscular Dystrophy

  2015cited by this paper
• Myocardial Fibrosis Burden Predicts Left Ventricular Ejection Fraction and Is Associated With Age and Steroid Treatment Duration in Duchenne Muscular Dystrophy

  2015influential reference
• Dystrophin–glycoprotein complex regulates muscle nitric oxide production through mechanoregulation of AMPK signaling

  2015cited by this paper
• Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy

  2015cited by this paper
• Dystrophic cardiomyopathy: role of TRPV2 channels in stretch-induced cell damage.

  2015cited by this paper
• Early Detection of Myocardial Bioenergetic Deficits: A 9.4 Tesla Complete Non Invasive 31P MR Spectroscopy Study in Mice with Muscular Dystrophy

  2015cited by this paper
• Crosstalk between RyR2 oxidation and phosphorylation contributes to cardiac dysfunction in mice with Duchenne muscular dystrophy.

  2015cited by this paper
• Becker muscular dystrophy severity is linked to the structure of dystrophin.

  2015cited by this paper
• Mitochondrial dysfunctions during progression of dystrophic cardiomyopathy.

  2015cited by this paper
• Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial.

  2015cited by this paper
• Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications.

  2015influential reference
• Glucocorticoid Therapy for Duchenne Cardiomyopathy: A Hobson's Choice?

  2015cited by this paper
• Membrane-stabilizing copolymers confer marked protection to dystrophic skeletal muscle in vivo

  2015cited by this paper
• Contemporary Cardiac Issues in Duchenne Muscular Dystrophy

  2015cited by this paper
• High-fidelity CRISPR-Cas9 variants with undetectable genome-wide off-targets

  2015cited by this paper
• Duchenne and Becker muscular dystrophies.

  2014influential reference
• NADPH oxidase-2 inhibition restores contractility and intracellular calcium handling and reduces arrhythmogenicity in dystrophic cardiomyopathy.

  2014cited by this paper
• A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy

  2014cited by this paper
• Enhanced currents through L-type calcium channels in cardiomyocytes disturb the electrophysiology of the dystrophic heart.

  2014cited by this paper
• Dystrobrevin increases dystrophin's binding to the dystrophin-glycoprotein complex and provides protection during cardiac stress.

  2014cited by this paper
• Prednisolone Attenuates Improvement of Cardiac and Skeletal Contractile Function and Histopathology by Lisinopril and Spironolactone in the mdx Mouse Model of Duchenne Muscular Dystrophy

  2014cited by this paper
• Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery.

  2014cited by this paper
• Cooperative international neuromuscular research group duchenne natural history study demonstrates insufficient diagnosis and treatment of cardiomyopathy in duchenne muscular dystrophy

  2014cited by this paper
• Dysregulation of calcium homeostasis in muscular dystrophies

  2014cited by this paper
• Partial restoration of cardiac function with ΔPDZ nNOS in aged mdx model of Duchenne cardiomyopathy.

  2014cited by this paper
• Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy

  2014cited by this paper
• Angiotensin II-Induced Production of Mitochondrial Reactive Oxygen Species: Potential Mechanisms and Relevance for Cardiovascular Disease

  2013cited by this paper
• High frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells

  2013cited by this paper
• X-ROS signaling in the heart and skeletal muscle: stretch-dependent local ROS regulates [Ca²⁺]i.

  2013cited by this paper
• VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects

  2013cited by this paper
• Non-ACE pathway-induced angiotensin II production.

  2013cited by this paper
• Prevalence and distribution of late gadolinium enhancement in a large population of patients with Duchenne muscular dystrophy: effect of age and left ventricular systolic function

  2013cited by this paper
• Nitric oxide signalling pathway in Duchenne muscular dystrophy mice: up-regulation of L-arginine transporters.

  2013cited by this paper
• A Randomized, Double-Blind Trial of Lisinopril and Losartan for the Treatment of Cardiomyopathy in Duchenne Muscular Dystrophy

  2013cited by this paper

• Inflammation in a severe model of dystrophic cardiomyopathy contains a high proportion of T cells that contribute to onset of pathology.

  2026cites this paper
• Heart failure in Duchenne's progressive muscular dystrophy (case report)

  2026cites this paper
• Dystrophin Loss in Engineered Heart Tissues Recapitulates Clinically Relevant Aspects of Dystrophic Cardiomyopathy.

  2025cites this paper
• The Importance of Early Diagnosis and Treatment to Limit the Impact of Dystrophic Cardiomyopathy—We’ve Seen This Film Before, and We Didn’t Like the Ending

  2025cites this paper
• Mitochondrial Coenzyme Q10 Delivery Improves Energy Production in Rat Cardiac Myoblasts and Duchenne Muscular Dystrophy Model Rat Cardiomyocytes.

  2025cites this paper
• Organoids in Genetic Disorders: from Disease Modeling to Translational Applications

  2025cites this paper
• Regional four-dimensional cardiac magnetic resonance strain predicts cardiomyopathy progression in Duchenne muscular dystrophy

  2025cites this paper
• Cardiac Cell and Animal Models for Duchenne Muscular Dystrophy in the Era of Gene Therapy and Precision Medicine

  2025cites this paper
• Sinus Tachycardia and Unrelieved Wall Stress Precede Left Ventricular Systolic Dysfunction During Preclinical Cardiomyopathic Changes in Duchenne Muscular Dystrophy

  2025cites this paper
• Diagnóstico y manejo de las complicaciones cardiacas en el paciente con distrofia muscular de Duchenne

  2025cites this paper
• Glucocorticoides y manejo cardíaco en pacientes con distrofia muscular de Duchenne

  2025cites this paper
• Activation of endogenous full-length utrophin by MyoAAV-UA as a therapeutic approach for Duchenne muscular dystrophy

  2025cites this paper
• Cardiac implications of chicken wooden breast myopathy

  2025cites this paper
• Early Cardiac Dysfunction in Duchenne Muscular Dystrophy: A Case Report and Literature Update

  2025cites this paper
• Association between age at loss of ambulation and cardiac function in adults with Duchenne muscular dystrophy.

  2025cites this paper
• Is Cardiac Transplantation Still a Contraindication in Patients with Muscular Dystrophy-Related End-Stage Dilated Cardiomyopathy? A Systematic Review

  2024cites this paper
• Failure to resolve inflammation contributes to juvenile onset cardiac damage in a mouse model of Duchenne muscular dystrophy

  2024cites this paper
• Is Duchenne gene therapy a suitable treatment despite its immunogenic class effect?

  2024cites this paper
• Primary Care Considerations for Individuals With Duchenne Muscular Dystrophy

  2024cites this paper
• Cardiomyopathy in Duchenne Muscular Dystrophy and the Potential for Mitochondrial Therapeutics to Improve Treatment Response

  2024cites this paper
• Cardiomyopathies Caused by Pathogenic Variants in the DMD Gene

  2024cites this paper
• How Can Proteomics Help to Elucidate the Pathophysiological Crosstalk in Muscular Dystrophy and Associated Multi-System Dysfunction?

  2024cites this paper
• Viltolarsen: From Preclinical Studies to FDA Approval.

  2023cites this paper
• Mechanisms of reduced myocardial energetics of the dystrophic heart.

  2023cites this paper
• Electrical impedance myography detects dystrophin-related muscle changes in mdx mice

  2023cites this paper
• Regional 4D Cardiac Magnetic Resonance Strain Predicts Cardiomyopathy Progression in Duchenne Muscular Dystrophy

  2023cites this paper
• Reduction in myocardial fibrosis in MDX mice on oral consumption of Aureobasidium Pullulans produced Neu REFIX Beta-glucans; holds potential as an adjuvant in managing post-transplantation organ fibrosis

  2023cites this paper
• Extracellular matrix contribution to disease progression and dysfunction in myopathy

  2023cites this paper
• Case report: A rare case of left ventricular noncompaction in two Chinese siblings with becker muscular dystrophy caused by deletion of exons 10 to 12 in the DMD gene

  2023cites this paper
• Extracellular Matrix Proteomics: The mdx-4cv Mouse Diaphragm as a Surrogate for Studying Myofibrosis in Dystrophinopathy

  2023cites this paper
• Left ventricular deformation and myocardial fibrosis in pediatric patients with Duchenne muscular dystrophy.

  2023cites this paper
• Cardiac therapies for Duchenne muscular dystrophy

  2023cites this paper
• Pharmacological Management of Dilated Cardiomyopathy in Duchenne Muscular Dystrophy: A Systematic Review.

  2023cites this paper
• Duchenne muscular dystrophy: disease mechanism and therapeutic strategies

  2023cites this paper
• The regulation of expression and splicing of transcription factors are related to the muscle damage caused by radiation in tree shrews.

  2023cites this paper
• A Protocol for Simultaneous In Vivo Imaging of Cardiac and Neuroinflammation in Dystrophin-Deficient MDX Mice Using [18F]FEPPA PET

  2023cites this paper
• Duchenne cardiomyopathy: targeting ROS and NOX4 as a promising therapeutic strategy

  2023cites this paper
• An overview of recent US-approved gene therapies for Duchenne muscular dystrophy and their respective clinical development programs

  2023cites this paper
• Narrative review of pediatric heart failure in the age of precision medicine

  2023cites this paper
• Extracellular vesicles and Duchenne muscular dystrophy pathology: Modulators of disease progression

  2023cites this paper
• Micro-dystrophin gene therapy demonstrates long-term cardiac efficacy in a severe Duchenne muscular dystrophy model

  2023cites this paper
• CB2 Receptor as Emerging Anti-Inflammatory Target in Duchenne Muscular Dystrophy

  2023cites this paper
• Bioinformatic Analysis of the Subproteomic Profile of Cardiomyopathic Tissue.

  2023cites this paper
• Analysis of Long Noncoding RNAs-Related Regulatory Mechanisms in Duchenne Muscular Dystrophy Using a Disease-Related lncRNA-mRNA Pathway Network

  2022cites this paper
• The Oxidative Balance Orchestrates the Main Keystones of the Functional Activity of Cardiomyocytes

  2022cites this paper
• Diversity of Dystrophin Gene Mutations and Disease Progression in a Contemporary Cohort of Duchenne Muscular Dystrophy

  2022cites this paper
• Sunitinib inhibits STAT3 phosphorylation in cardiac muscle and prevents cardiomyopathy in the mdx mouse model of Duchenne muscular dystrophy.

  2022cites this paper
• Inhibition of PKCθ Improves Dystrophic Heart Phenotype and Function in a Novel Model of DMD Cardiomyopathy

  2022influential citation
• In Vivo Magnetic Resonance Spectroscopy Methods for Investigating Cardiac Metabolism

  2022cites this paper
• A Long-Term Study Evaluating the Effects of Nicorandil Treatment on Duchenne Muscular Dystrophy-Associated Cardiomyopathy in mdx Mice

  2022influential citation
• Microtubule-Connexin-43 regulation suppresses arrhythmias and fibrosis in Duchenne muscular dystrophy mice

  2022cites this paper
• Biomarkers in Duchenne Muscular Dystrophy

  2022cites this paper
• Sarcoplasmic Reticulum Ca2+ Dysregulation in the Pathophysiology of Inherited Arrhythmia: An Update.

  2022cites this paper
• Neuromuscular diseases and their cardiac manifestations under the spectrum of cardiovascular imaging

  2022cites this paper
• The role of the dystrophin glycoprotein complex in muscle cell mechanotransduction

  2022cites this paper
• A microtubule-Connexin-43 regulatory link suppresses arrhythmias and cardiac fibrosis in Duchenne muscular dystrophy mice.

  2022cites this paper
• Prevention of Tracheo-Innominate Artery Fistula Formation as a Complication of Tracheostomy: Two Case Reports

  2022cites this paper
• A systematic review of pharmacologic therapies for the cardiomyopathy of Duchenne muscular dystrophy

  2021cites this paper
• Targeted addition of mini-dystrophin into rDNA locus of Duchenne muscular dystrophy patient-derived iPSCs.

  2021cites this paper
• Cardiac CIP protein regulates dystrophic cardiomyopathy.

  2021cites this paper
• Developing DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies

  2021cites this paper
• Pharmacological Profile of Viltolarsen for the Treatment of Duchenne Muscular Dystrophy: A Japanese Experience

  2021cites this paper
• Cardiac Myoediting Attenuates Cardiac Abnormalities in Human and Mouse Models of Duchenne Muscular Dystrophy

  2021cites this paper
• Accelerating the Mdx Heart Histo-Pathology through Physical Exercise

  2021cites this paper
• Cardiomyopathy in Duchenne Muscular Distrophy: Clinical Insights and Therapeutic Implications

  2021cites this paper
• Focus on the road to modelling cardiomyopathy in muscular dystrophy.

  2021cites this paper
• Mass Spectrometric Profiling of Extraocular Muscle and Proteomic Adaptations in the mdx-4cv Model of Duchenne Muscular Dystrophy

  2021cites this paper
• Dilated cardiomyopathy as the initial presentation of Becker muscular dystrophy: a systematic review of published cases

  2021cites this paper
• Cardioprotective effect of nicorandil on isoproterenol induced cardiomyopathy in the Mdx mouse model

  2021cites this paper
• Duchenne Muscular Dystrophy Patients: Troponin Leak in Asymptomatic and Implications for Drug Toxicity Studies

  2021cites this paper
• Prevalence of Bladder and Bowel Dysfunction in Duchenne Muscular Dystrophy Using the Childhood Bladder and Bowel Dysfunction Questionnaire

  2021cites this paper
• Complexity of skeletal muscle degeneration: multi-systems pathophysiology and organ crosstalk in dystrophinopathy

  2021cites this paper
• The clinical utility of pediatric cardiomyopathy genetic testing: From diagnosis to a precision medicine-based approach to care.

  2021cites this paper
• Electrocardiographic prediction of late gadolinium enhancement on cardiac magnetic resonance in Becker muscular dystrophy.

  2021cites this paper
• Disrupted Calcium Homeostasis in Duchenne Muscular Dystrophy: A Common Mechanism behind Diverse Consequences

  2021cites this paper
• Clinical Management of DMD-Associated Cardiomyopathy

  2021cites this paper
• To be, or not to be… Guillain-Barré Syndrome.

  2021cites this paper
• Endoplasmic Reticulum-Mitochondria Contacts: A Potential Therapy Target for Cardiovascular Remodeling-Associated Diseases

  2021cites this paper
• A Dystrophin Exon-52 Deleted Miniature Pig Model of Duchenne Muscular Dystrophy and Evaluation of Exon Skipping

  2021cites this paper
• The multifaceted view of heart problem in Duchenne muscular dystrophy

  2021cites this paper
• Proteomic analysis identifies key differences in the cardiac interactomes of dystrophin and micro-dystrophin

  2021cites this paper
• Effect of Verapamil, an L-Type Calcium Channel Inhibitor, on Caveolin-3 Expression in Septic Mouse Hearts

  2021cites this paper
• Therapeutic aspects of cell signaling and communication in Duchenne muscular dystrophy

  2021cites this paper
• Impact of estrogen deficiency on diaphragm and leg muscle contractile function in female mdx mice

  2021cites this paper
• CPAA_A_288842 235..242

  2021cites this paper
• Current Pharmacological Strategies for Duchenne Muscular Dystrophy

  2021cites this paper
• Micro-dystrophin gene therapy prevents heart failure in an improved Duchenne muscular dystrophy cardiomyopathy mouse model

  2021cites this paper
• Histopathology of Duchenne muscular dystrophy in correlation with changes in proteomic biomarkers.

  2021cites this paper
• Neurological complications of cardiomyopathies.

  2021cites this paper
• A novel mouse model of Duchenne muscular dystrophy carrying a multi-exonic Dmd deletion exhibits progressive muscular dystrophy and early-onset cardiomyopathy

  2020cites this paper
• Neuromuscular Urgencies and Emergencies

  2020influential citation
• Progressive Proteome Changes in the Myocardium of a Pig Model for Duchenne Muscular Dystrophy

  2020cites this paper
• Proteome-wide Changes in the mdx-4cv Spleen due to Pathophysiological Cross Talk with Dystrophin-Deficient Skeletal Muscle

  2020cites this paper
• A novel ex vivo protocol to mimic human walking gait: implications for Duchenne muscular dystrophy.

  2020cites this paper
• DMD Pluripotent Stem Cell Derived Cardiac Cells Recapitulate in vitro Human Cardiac Pathophysiology

  2020cites this paper
• A retooled drug that restores ionic balance and cardiac function in dystrophin deficient hearts.

  2020cites this paper
• Long‐term human IgG treatment improves heart and muscle function in a mouse model of Duchenne muscular dystrophy

  2020cites this paper
• From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases.

  2020cites this paper
• Proteomic profiling of fatty acid binding proteins in muscular dystrophy

  2020cites this paper
• Loss-of-Function Variants in Cytoskeletal Genes Are Associated with Early-Onset Atrial Fibrillation

  2020influential citation